Skip to main content

Diagnosis or Exclusion of von Willebrand Disease Using Laboratory Testing

  • Protocol
  • First Online:
Hemostasis and Thrombosis

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1646))

Abstract

von Willebrand disease (VWD) is a common bleeding disorder diagnosed based on clinical features and following laboratory testing. VWD is due to deficiencies or defects in the plasma protein von Willebrand factor (VWF), a large adhesive protein with multiple activities. Laboratory testing therefore centers on assessment of VWF protein level using VWF antigen (VWF:Ag), as well as assays that measure VWF activity, most notably platelet glycoprotein (GP) Ib and collagen binding (VWF:CB) activities. Decreases in VWF:Ag and VWF activities, as well as the pattern of such changes, help define VWD and its type. Classically, the most often used assay for measuring GPIb binding activity was the ristocetin cofactor assay (VWF:RCo), which historically measured agglutination of fixed human platelets by VWF in the presence of ristocetin. This assay is now often replaced or supplemented with other assays based on binding of VWF to recombinant GPIb, generally without the use of platelets, and with or without ristocetin. This chapter briefly reviews laboratory tests for VWD, as well as recommended approaches to use of such assays to help diagnose or exclude VWD in patients showing clinical features.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

Ag:

von Willebrand factor antigen result

APTT:

Activated partial thromboplastin time

CB/Ag:

Ratio of VWF:CB to VWF:Ag

CBC:

Complete blood count

FVIII:C:

Factor VIII coagulant

FVIIIB:

Level of factor VIII bound in a von Willebrand factor: FVIII binding assay

GPIb binding/Ag:

VWF glycoprotein Ib binding to VWF antigen ratio (for the purpose of this review, these would include classical VWF:RCo and newer methodologies now defined as “VWF:GPIbR” and “VWF:GPIbM” (refer to Table 1))

PFA:

Platelet function analyzer (−100 or −200)

PT:

Prothrombin time

PT-VWD:

Platelet-type VWD

RCo/Ag:

Ratio of VWF:RCo to VWF:Ag

RIPA:

Ristocetin-induced platelet agglutination assay

VWD:

von Willebrand disease/disorder

VWF:

von Willebrand factor

VWF:Ag:

von Willebrand factor antigen (assay)

VWF:CB:

von Willebrand factor collagen binding (assay)

VWF:FVIIIB:

von Willebrand factor: FVIII binding assay

VWF:RCo:

von Willebrand factor ristocetin cofactor (assay)

References

  1. Favaloro EJ (2011) Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost 37:425–426

    Article  Google Scholar 

  2. Favaloro EJ, Pasalic L, Curnow J (2016) Laboratory tests used to help diagnose von Willebrand disease: an update. Pathology 48:303–318

    Article  CAS  PubMed  Google Scholar 

  3. Favaloro EJ (2014) Diagnosing von Willebrand disease: a short history of laboratory milestones and innovations, plus current status, challenges, and solutions. Semin Thromb Hemost 40:551–570

    Article  CAS  PubMed  Google Scholar 

  4. Just S (2017) Laboratory testing for von Willebrand disease: the past, present, and future state of play for von Willebrand factor assays that measure platelet binding activity, with or without Ristocetin. Semin Thromb Hemost 43:75–91

    Google Scholar 

  5. Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J (2015) Platelet dependent von Willebrand factor activity. Nomenclature and methodology: communication from SSC of the ISTH. J Thromb Haemost 13:1345–1350

    Article  PubMed  Google Scholar 

  6. Mazurier C, Rodeghiero F. von Willebrand Factor Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2001) Recommended abbreviations for von Willebrand Factor and its activities. Thromb Haemost 86:712

    CAS  PubMed  Google Scholar 

  7. Sadler JE, Budde U, Eikenboom JC, Working Party on von Willebrand Disease Classification et al (2006) Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 4:2103–2114

    Article  CAS  PubMed  Google Scholar 

  8. Favaloro EJ, Pasalic L, Curnow J (2017) Monitoring therapy during treatment of von Willebrand disease. Semin Thromb Hemost 43:338–354

    Google Scholar 

  9. Curnow J, Pasalic L, Favaloro EJ (2016) Treatment of von Willebrand disease. Semin Thromb Hemost 42:133–146

    Article  CAS  PubMed  Google Scholar 

  10. Favaloro EJ, Bonar RA, Meiring M, Duncan E, Mohammed S, Sioufi J, Marsden K (2014) Evaluating errors in the laboratory identification of von Willebrand disease in the real world. Thromb Res 134:393–403

    Article  CAS  PubMed  Google Scholar 

  11. Favaloro EJ, Bonar RA, Mohammed S, Arbelaez A, Niemann F, Freney R, Meiring M, Sioufi J, Marsden K (2016) Type 2M von Willebrand disease – more often misidentified than correctly identified. Haemophilia 22:e145–e155

    Article  CAS  PubMed  Google Scholar 

  12. Favaloro, E.J., Bonar, R., Kershaw, G., Sioufi, J., Baker, R., Hertzberg, M., Street, A., Marsden, K (on behalf of the RCPA QAP in Haematology) (2006) Reducing errors in identification of von Willebrand disease: the experience of the Royal college of Pathologists of Australasia Quality Assurance Program. Semin Thromb Hemost 32, 505–513.

    Google Scholar 

  13. Favaloro EJ, Mohammed S (2014) Towards improved diagnosis of von Willebrand disease: comparative evaluations of several automated von Willebrand factor antigen and activity assays. Thromb Res 134:1292–1300

    Article  CAS  PubMed  Google Scholar 

  14. Favaloro EJ, Mohammed S (2016) Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease. Thromb Res 141:202–211

    Article  CAS  PubMed  Google Scholar 

  15. Castellone DD, Adcock DM (2017) Factor VIII activity and inhibitor assays in the diagnosis and treatment of hemophilia A. Semin Thromb Hemost 43:320–330

    Google Scholar 

  16. Kitchen S, Tiefenbacher S, Gosselin R (2017) Factor activity assays for monitoring extended half life FVIII and factor IX replacement therapies. Semin Thromb Hemost 43(3):331–337

    Article  CAS  PubMed  Google Scholar 

  17. Blanchette VS, Srivastava A (2015) Definitions in hemophilia: resolved and unresolved issues. Semin Thromb Hemost 41:819–825

    Article  PubMed  Google Scholar 

  18. Favaloro EJ (2010) Genetic testing for von Willebrand disease: the case against. J Thromb Haemost 8:6–12

    Article  CAS  PubMed  Google Scholar 

  19. Laffan MA, Lester W, O'Donnell JS, Will A, Tait RC, Goodeve A, Millar CM, Keeling DM (2014) The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 167:453–465

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Emmanuel J. Favaloro .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media LLC

About this protocol

Cite this protocol

Favaloro, E.J. (2017). Diagnosis or Exclusion of von Willebrand Disease Using Laboratory Testing. In: Favaloro, E., Lippi, G. (eds) Hemostasis and Thrombosis. Methods in Molecular Biology, vol 1646. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7196-1_29

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7196-1_29

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7194-7

  • Online ISBN: 978-1-4939-7196-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics